Cibc World Market Inc. Takes $2.26 Million Position in Illumina, Inc. $ILMN

Key Points

• CIBC World Market purchased 12,852 Illumina shares worth approximately $2.26 million during the second quarter. Institutional investors collectively own 89.42% of the company.
• Illumina reported quarterly earnings of $1.31 per share, beating estimates by $0.08, while revenue rose 9.4% year over year to $1.16 billion. The company issued fiscal 2026 EPS guidance of $5.30–$5.40.
• Despite generally positive analyst coverage, insiders sold 1.87 million shares worth nearly $368 million over the past 90 days. Analysts’ average rating is “Hold”, with an average price target of $188.40.

Cibc World Market Inc. purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 12,852 shares of the life sciences company's stock, valued at approximately $2,260,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Capital World Investors increased its stake in Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company's stock valued at $2,636,483,000 after buying an additional 124,323 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Illumina in the 2nd quarter worth approximately $3,374,423,000. State Street Corp boosted its stake in shares of Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company's stock worth $811,895,000 after buying an additional 190,324 shares during the last quarter. WCM Investment Management LLC grew its holdings in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock valued at $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company's stock valued at $580,531,000 after acquiring an additional 1,028,099 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Illumina

In related news, Director Keith A. Meister sold 457,858 shares of the company's stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,874,458 shares of company stock worth $367,996,424 over the last ninety days. Company insiders own 2.90% of the company's stock.

Illumina Stock Down 0.1%

Shares of NASDAQ ILMN opened at $224.84 on Thursday. Illumina, Inc. has a one year low of $88.00 and a one year high of $227.70. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The business's fifty day moving average price is $191.66 and its 200-day moving average price is $154.42. The stock has a market capitalization of $33.95 billion, a PE ratio of 41.95, a P/E/G ratio of 3.17 and a beta of 1.45.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the company earned $1.19 EPS. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Evercore reiterated an "outperform" rating on shares of Illumina in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft cut Illumina to a "hold" rating in a research note on Wednesday, August 5th. Guggenheim increased their price target on shares of Illumina from $200.00 to $226.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Barclays lifted their price objective on shares of Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Illumina from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, Illumina currently has an average rating of "Hold" and an average price target of $188.40.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source